Core Insights - TriSalus Life Sciences Inc. (NASDAQ:TLSI) is preparing for its quarterly earnings release, focusing on innovative oncology treatments with Wall Street expecting an earnings per share (EPS) of -$0.17 and projected revenue of approximately $11.76 million [1][3] Financial Performance - The company has a negative price-to-earnings (P/E) ratio of -4.67, indicating challenges in profitability [2][4] - TLSI's price-to-sales ratio is about 4.66, suggesting investors are willing to pay $4.66 for every dollar of sales [5] - The enterprise value to sales ratio stands at around 4.86, reflecting the company's valuation relative to its sales [5] - The enterprise value to operating cash flow ratio is approximately -6.17, indicating negative operating cash flow [5] - The earnings yield is about -21.44%, showing negative earnings relative to its share price [6] - The debt-to-equity ratio is approximately -1.73, suggesting more liabilities than equity [6] - The current ratio of around 4.08 indicates a strong ability to cover short-term liabilities with short-term assets [6] Company Activities - TLSI is actively engaging in investor relations, participating in the Canaccord Genuity MedTech, Diagnostics, and Digital Health conference [2][4] - The company is hosting a virtual event on November 12, 2025, to discuss the TriNav Infusion System, emphasizing its commitment to improving treatment outcomes for solid tumors [4]
TriSalus Life Sciences Inc. (NASDAQ: TLSI) Quarterly Earnings Preview